9 In 2023, Aggarwal et al. published the results of a phase 1 trial of single dose 177 Lu-PSMA-617 followed by maintenance pembrolizumab in mCRPC patients. From an efficacy standpoint, 44% of patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback